RT Journal Article
SR Electronic
T1 Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.06.20055475
DO 10.1101/2020.04.06.20055475
A1 Chen, Xiangyu
A1 Li, Ren
A1 Pan, Zhiwei
A1 Qian, Chunfang
A1 Yang, Yang
A1 You, Renrong
A1 Zhao, Jing
A1 Liu, Pinghuang
A1 Gao, Leiqiong
A1 Li, Zhirong
A1 Huang, Qizhao
A1 Xu, Lifan
A1 Tang, Jianfang
A1 Tian, Qin
A1 Yao, Wei
A1 Hu, Li
A1 Yan, Xiaofeng
A1 Zhou, Xinyuan
A1 Wu, Yuzhang
A1 Deng, Kai
A1 Zhang, Zheng
A1 Qian, Zhaohui
A1 Chen, Yaokai
A1 Ye, Lilin
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055475.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). To date, no prophylactic vaccines or approved therapeutic agents are available for preventing and treating this highly transmittable disease. Here we report two monoclonal antibodies (mAbs) cloned from memory B cells of patients recently recovered from COVID-19, and both mAbs specifically bind to the spike (S) protein of SARS-CoV-2, block the binding of receptor binding domain (RBD) of SARS-CoV-2 to human angiotensin converting enzyme 2 (hACE2), and effectively neutralize S protein-pseudotyped virus infection. These human mAbs hold the promise for the prevention and treatment of the ongoing pandemic of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Natural Science Fund for Distinguished Young Scholars (No. 31825011 to L.Y.) and the Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control (No. cstc2020jscx-2 to L.Y.; No. cstc2020jscx-fyzx0074 to Y.C.; cstc2020jscx-fyzx0135 to Y.C.).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in the manuscript are of availability.